ACADIA Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ACAD)

$28.37 0.47 (1.68 %)
(As of 01/16/2018 04:00 PM ET)
Previous Close$27.90
Today's Range$27.60 - $28.44
52-Week Range$25.06 - $41.20
Volume1.69 million shs
Average Volume2.07 million shs
Market Capitalization$3.45 billion
P/E Ratio-11.53
Dividend YieldN/A
Beta3.79

About ACADIA Pharmaceuticals (NASDAQ:ACAD)

ACADIA Pharmaceuticals logoACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist (SSIA), preferentially targeting 5-HT2A receptors. The Company is conducting a Phase II trial, referred to as the SERENE Study, designed to examine the efficacy and safety of pimavanserin as a treatment for Alzheimer's disease (AD) Agitation. It is also conducting a Phase III, six-week, randomized, double-blind, placebo-controlled, multi-center, outpatient study, referred to as the ENHANCE-1 study, designed to examine the use of pimavanserin in patients with schizophrenia.

Receive ACAD News and Ratings via Email

Sign-up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:ACAD
CUSIPN/A
Phone+1-858-5582871

Debt

Debt-to-Equity RatioN/A
Current Ratio11.12%
Quick Ratio10.97%

Price-To-Earnings

Trailing P/E Ratio-11.5325203252033
Forward P/E Ratio-11.77
P/E GrowthN/A

Sales & Book Value

Annual Sales$17.33 million
Price / Sales203.34
Cash FlowN/A
Price / CashN/A
Book Value$4.28 per share
Price / Book6.63

Profitability

Trailing EPS($2.46)
Net Income$-271,390,000.00
Net Margins-320.71%
Return on Equity-67.68%
Return on Assets-61.88%

Miscellaneous

Employees370
Outstanding Shares124,210,000

ACADIA Pharmaceuticals (NASDAQ:ACAD) Frequently Asked Questions

What is ACADIA Pharmaceuticals' stock symbol?

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) released its quarterly earnings data on Tuesday, November, 7th. The biopharmaceutical company reported ($0.53) EPS for the quarter, beating analysts' consensus estimates of ($0.63) by $0.10. The biopharmaceutical company had revenue of $35.58 million for the quarter, compared to analysts' expectations of $32.03 million. ACADIA Pharmaceuticals had a negative return on equity of 67.68% and a negative net margin of 320.71%. The firm's quarterly revenue was up 571.3% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.61) earnings per share. View ACADIA Pharmaceuticals' Earnings History.

When will ACADIA Pharmaceuticals make its next earnings announcement?

ACADIA Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February, 27th 2018. View Earnings Estimates for ACADIA Pharmaceuticals.

Where is ACADIA Pharmaceuticals' stock going? Where will ACADIA Pharmaceuticals' stock price be in 2018?

12 analysts have issued twelve-month price objectives for ACADIA Pharmaceuticals' shares. Their forecasts range from $45.00 to $61.00. On average, they anticipate ACADIA Pharmaceuticals' stock price to reach $51.27 in the next twelve months. View Analyst Ratings for ACADIA Pharmaceuticals.

What are Wall Street analysts saying about ACADIA Pharmaceuticals stock?

Here are some recent quotes from research analysts about ACADIA Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia. " (1/15/2018)
  • 2. HC Wainwright analysts commented, "HARMONY Study Initiation: Killing Multiple" Birds With One Stone? Reit Buy and $60 PT Initiation of the Ph3 HARMONY study is one step forward with our bull thesis. With the initiation of HARMONY study in dementia-related psychosis (DRP) and discontinuation of SEREN study in AD agitation, we applaud what we view as a smart move by Acadia of pursuing a broader indication for pimavanserin, and more importantly, doing so with a solid clinical plan moving forward. At first glance, the seemingly bold move into DRP from ADP may appear over-ambitious (killing multiple" birds with one stone). However, we note that a psychosis focus/approach may prove to be a smart play from both the commercial point of view and also from the mechanistic perspective. The blessing from the FDA with a Breakthrough Designation further elevates our sanguine outlook for the program. We highlight the significant upside coming with the DRP expansion as the target market is potentially bigger than ADP alone (if we assume ADP comprises 70% of the DRP)." (10/5/2017)
  • 3. Needham & Company LLC analysts commented, "Acadia reported $11.9M in 4Q16 Nuplazid sales, above our $9.0M estimate. Mgmt noted steady growth in number of prescribers, repeat prescribers, and new patients. Company also announced plan to expand sales force by 20 reps to address long-term care opportunity. There are no immediate plans to provide 2017 sales guidance. We believe stock is attractive given Nuplazid launch trajectory and likelihood for label expansion in long-term. Stock likely to be driven by sales in 2017 and Phase 2/3 results in other indications in 2018/ 2019. Acadia may be an attractive M&A target. BUY." (3/1/2017)

Who are some of ACADIA Pharmaceuticals' key competitors?

Who are ACADIA Pharmaceuticals' key executives?

ACADIA Pharmaceuticals' management team includes the folowing people:

  • Stephen R. Biggar M.D. Ph.D., Chairman of the Board (Age 46)
  • Stephen R. Davis, President, Chief Executive Officer, Director (Age 56)
  • Todd S. Young, Executive Vice President, Chief Financial Officer (Age 45)
  • Glenn F. Baity, Executive Vice President, General Counsel, Secretary (Age 47)
  • Srdjan Stankovic M.D., Executive Vice President, Head - Research and Development (Age 60)
  • Michael J. Yang, Executive Vice President, Chief Commercial Officer (Age 55)
  • Edmund P. Harrigan M.D., Director (Age 64)
  • Julian C. Baker, Independent Director (Age 50)
  • Laura A. Brege, Independent Director (Age 59)
  • James M. Daly, Independent Director (Age 55)

How do I buy ACADIA Pharmaceuticals stock?

Shares of ACADIA Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ACADIA Pharmaceuticals' stock price today?

One share of ACADIA Pharmaceuticals stock can currently be purchased for approximately $28.37.

How big of a company is ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals has a market capitalization of $3.45 billion and generates $17.33 million in revenue each year. The biopharmaceutical company earns $-271,390,000.00 in net income (profit) each year or ($2.46) on an earnings per share basis. ACADIA Pharmaceuticals employs 370 workers across the globe.

How can I contact ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals' mailing address is 3611 Valley Centre Dr Ste 300, SAN DIEGO, CA 92130-3331, United States. The biopharmaceutical company can be reached via phone at +1-858-5582871 or via email at [email protected]


MarketBeat Community Rating for ACADIA Pharmaceuticals (ACAD)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  481 (Vote Outperform)
Underperform Votes:  212 (Vote Underperform)
Total Votes:  693
MarketBeat's community ratings are surveys of what our community members think about ACADIA Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

ACADIA Pharmaceuticals (NASDAQ:ACAD) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.832.832.772.71
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $51.27$49.42$47.54$43.00
Price Target Upside: 73.04% upside66.78% upside32.94% upside54.40% upside

ACADIA Pharmaceuticals (NASDAQ:ACAD) Consensus Price Target History

Price Target History for ACADIA Pharmaceuticals (NASDAQ:ACAD)

ACADIA Pharmaceuticals (NASDAQ:ACAD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/8/2017HC WainwrightReiterated RatingBuy$60.00N/AView Rating Details
11/7/2017CowenReiterated RatingBuy$46.00N/AView Rating Details
10/12/2017Jefferies GroupReiterated RatingBuy$47.00N/AView Rating Details
10/9/2017Leerink SwannReiterated RatingMarket PerformN/AView Rating Details
10/6/2017Goldman Sachs GroupReiterated RatingNeutral$45.00N/AView Rating Details
10/5/2017JPMorgan Chase & Co.Set Price TargetBuy$50.00N/AView Rating Details
10/5/2017Piper Jaffray CompaniesReiterated RatingBuy$54.00 -> $61.00N/AView Rating Details
10/5/2017Bank of AmericaBoost Price TargetBuy -> Positive$40.00 -> $46.00N/AView Rating Details
10/5/2017JMP SecuritiesBoost Price TargetOutperform$47.00 -> $50.00N/AView Rating Details
10/2/2017Ladenburg Thalmann Financial ServicesReiterated RatingBuy$48.00 -> $50.00LowView Rating Details
9/17/2017Needham & Company LLCReiterated RatingBuy$49.00LowView Rating Details
5/22/2017Rodman & RenshawReiterated RatingBuy$60.00LowView Rating Details
10/19/2016Roth CapitalReiterated RatingNeutral$25.00N/AView Rating Details
8/5/2016AegisDowngradeBuy -> Hold$54.00 -> $41.00N/AView Rating Details
(Data available from 1/16/2016 forward)

Earnings

ACADIA Pharmaceuticals (NASDAQ:ACAD) Earnings History and Estimates Chart

Earnings by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

ACADIA Pharmaceuticals (NASDAQ ACAD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/26/2018($0.58)N/AView Earnings Details
11/7/2017Q3 2017($0.63)($0.53)$32.03 million$35.58 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.72)($0.55)$20.02 million$30.50 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.73)($0.72)$15.17 million$15.30 millionViewListenView Earnings Details
2/28/2017Q416($0.65)($0.65)$9.05 million$12.00 millionViewListenView Earnings Details
11/7/2016Q316($0.56)($0.61)$2.90 million$5.30 millionViewListenView Earnings Details
8/4/2016Q216($0.49)($0.63)$0.71 million$0.97 millionViewListenView Earnings Details
5/5/2016Q116($0.42)($0.45)$0.22 millionViewListenView Earnings Details
2/29/2016Q415($0.38)($0.45)$0.02 millionViewListenView Earnings Details
11/5/2015Q315($0.40)($0.39)$0.05 million$0.04 millionViewListenView Earnings Details
8/6/2015Q215($0.33)($0.39)$0.06 millionViewListenView Earnings Details
5/7/2015Q115($0.25)($0.40)$0.09 millionViewListenView Earnings Details
2/26/2015Q414($0.26)($0.28)$0.08 million$0.05 millionViewListenView Earnings Details
11/10/2014Q3($0.12)($0.25)$0.02 millionViewListenView Earnings Details
8/5/2014Q2($0.17)($0.22)$0.10 million$0.03 millionViewListenView Earnings Details
5/6/2014Q1($0.13)($0.19)$0.50 million$0.03 millionViewListenView Earnings Details
2/27/2014Q4($0.14)($0.13)ViewListenView Earnings Details
11/6/2013Q3 2013($0.12)($0.12)ViewN/AView Earnings Details
8/6/2013Q2 2013($0.09)($0.11)$0.45 million$451.00 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.08)($0.08)$0.45 million$0.42 millionViewListenView Earnings Details
3/12/2013Q4 2012($0.08)($0.11)ViewN/AView Earnings Details
11/5/2012Q312($0.09)($0.04)$1.90 million$3.50 millionViewN/AView Earnings Details
8/8/2012Q2 2012($0.12)($0.10)ViewN/AView Earnings Details
5/8/2012Q1 2012($0.11)($0.12)ViewN/AView Earnings Details
3/6/2012Q4 2011($0.10)($0.10)ViewN/AView Earnings Details
11/9/2011Q3 2011($0.10)($0.10)ViewN/AView Earnings Details
8/10/2011Q2 2011($0.15)($0.10)ViewN/AView Earnings Details
5/10/2011Q1 2011($0.11)($0.12)ViewN/AView Earnings Details
3/10/2011Q4 2010$0.69$0.74ViewN/AView Earnings Details
11/9/2010Q3 2010($0.17)($0.11)ViewN/AView Earnings Details
8/9/2010Q2 2010($0.16)($0.11)ViewN/AView Earnings Details
5/10/2010Q1 2010($0.17)($0.14)ViewN/AView Earnings Details
3/9/2010Q4 2009($0.19)($0.23)ViewN/AView Earnings Details
11/9/2009Q3 2009($0.27)($0.23)ViewN/AView Earnings Details
8/5/2009Q2 2009($0.34)($0.34)ViewN/AView Earnings Details
5/11/2009Q1 2009($0.36)($0.40)ViewN/AView Earnings Details
3/9/2009Q4 2008($0.38)($0.38)ViewN/AView Earnings Details
11/5/2008Q3 2008($0.43)($0.36)ViewN/AView Earnings Details
8/5/2008Q2 2008($0.46)($0.49)ViewN/AView Earnings Details
5/5/2008Q1 2008($0.46)($0.44)ViewN/AView Earnings Details
3/5/2008Q4 2007($0.46)($0.46)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

ACADIA Pharmaceuticals (NASDAQ:ACAD) Earnings Estimates

2018 EPS Consensus Estimate: ($1.91)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.55)($0.55)($0.55)
Q2 20181($0.50)($0.50)($0.50)
Q3 20181($0.45)($0.45)($0.45)
Q4 20181($0.41)($0.41)($0.41)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for ACADIA Pharmaceuticals (NASDAQ:ACAD)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

ACADIA Pharmaceuticals (NASDAQ ACAD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 22.25%
Institutional Ownership Percentage: 94.02%
Insider Trades by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Institutional Ownership by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

ACADIA Pharmaceuticals (NASDAQ ACAD) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/2/2018Glenn BaityEVPSell74,321$30.14$2,240,034.94View SEC Filing  
1/2/2018Laura BregeDirectorSell25,000$30.06$751,500.0015,000View SEC Filing  
10/5/2017Glenn BaityEVPSell37,500$40.91$1,534,125.00View SEC Filing  
8/30/2017Glenn BaityEVPSell26,507$34.87$924,299.0994,163View SEC Filing  
8/9/2017Glenn BaityEVPSell14,322$34.88$499,551.3678,578View SEC Filing  
7/20/2017Glenn BaityEVPSell38,097$30.00$1,142,910.00109,253View SEC Filing  
6/22/2017Glenn BaityEVPSell1,903$30.00$57,090.0083,059View SEC Filing  
2/16/2017Terrence O. MooreEVPSell157,540$39.77$6,265,365.80View SEC Filing  
12/27/2016Glenn BaityEVPSell9,800$30.46$298,508.0081,363View SEC Filing  
12/20/2016Glenn BaityEVPSell10,000$30.00$300,000.00View SEC Filing  
8/16/2016Edmund HarriganDirectorBuy1,000$32.97$32,970.001,000View SEC Filing  
8/10/2016Bros. Advisors Lp BakerDirectorBuy1,303,030$33.00$42,999,990.00View SEC Filing  
7/12/2016Glenn BaityEVPSell16,000$35.00$560,000.0066,978View SEC Filing  
7/11/2016Glenn BaityEVPSell4,057$35.00$141,995.0066,978View SEC Filing  
4/18/2016Leslie L IversenDirectorSell33,697$33.53$1,129,860.4169,824View SEC Filing  
4/1/2016Bros. Advisors Lp BakerDirectorBuy1,449,090$27.08$39,241,357.20View SEC Filing  
1/7/2016L.P. 14159DirectorBuy2,586,206$29.00$74,999,974.00View SEC Filing  
11/11/2015Leslie L. IversenDirectorSell30,000$36.01$1,080,300.0036,127View SEC Filing  
1/15/2015Michael T BorerDirectorSell27,973$33.02$923,668.46View SEC Filing  
1/14/2015Uli HacksellCEOSell30,000$33.98$1,019,400.00View SEC Filing  
12/15/2014Mary Ann GrayDirectorSell12,250$31.74$388,815.00View SEC Filing  
12/15/2014Uli HacksellCEOSell30,000$31.00$930,000.00View SEC Filing  
11/26/2014Michael T BorerDirectorSell15,000$30.05$450,750.00View SEC Filing  
11/26/2014Roger MillsCMOSell25,000$30.09$752,250.00View SEC Filing  
11/24/2014Uli HacksellCEOSell30,000$29.28$878,400.00View SEC Filing  
11/21/2014William Mcdowall WellsDirectorSell5,810$29.00$168,490.00View SEC Filing  
10/8/2014Uli HacksellCEOSell30,000$24.15$724,500.00View SEC Filing  
9/15/2014Laura BregeDirectorSell10,000$28.07$280,700.00View SEC Filing  
9/12/2014William Mcdowall WellsDirectorSell9,190$29.15$267,888.50View SEC Filing  
9/10/2014Uli HacksellCEOSell30,000$27.36$820,800.00View SEC Filing  
8/15/2014Uli HacksellCEOSell15,000$22.89$343,350.00View SEC Filing  
7/14/2014Uli HacksellCEOSell20,000$22.22$444,400.00View SEC Filing  
6/16/2014Uli HacksellCEOSell20,000$23.10$462,000.00View SEC Filing  
6/9/2014William Mcdowall WellsDirectorSell15,000$23.03$345,450.00View SEC Filing  
5/1/2014Torsten RasmussenDirectorSell32,857$20.03$658,125.71View SEC Filing  
4/15/2014Uli HacksellCEOSell25,000$17.75$443,750.00View SEC Filing  
4/4/2014Thomas AasenCFOSell15,000$22.48$337,200.0023,848View SEC Filing  
4/4/2014Torsten RasmussenDirectorSell30,000$21.98$659,400.00View SEC Filing  
3/5/2014Bros. Advisors Lp BakerDirectorBuy526,316$28.50$15,000,006.00View SEC Filing  
2/26/2014Glenn BaityVPSell42,000$30.28$1,271,760.0047,788View SEC Filing  
11/1/2013Torsten RasmussenDirectorSell37,692$23.00$866,916.00View SEC Filing  
11/1/2013Uli HacksellCEOSell15,000$23.24$348,600.00View SEC Filing  
10/10/2013Laura BregeDirectorSell10,000$21.63$216,300.00View SEC Filing  
10/1/2013Thomas H AasenCFOSell30,000$27.87$836,100.00View SEC Filing  
9/20/2013Roger MillsCMOSell35,965$25.01$899,484.6515,775View SEC Filing  
9/12/2013Lester Ph KaplanDirectorSell66,356$22.90$1,519,552.408,500View SEC Filing  
9/10/2013Laura BregeDirectorSell46,153$22.80$1,052,288.40View SEC Filing  
9/3/2013Torsten RasmussenDirectorSell40,000$20.28$811,200.00View SEC Filing  
8/26/2013Mary Ann GrayDirectorSell15,000$20.68$310,200.00View SEC Filing  
8/13/2013Thomas AasenCFOSell60,000$20.15$1,209,000.0031,585View SEC Filing  
8/13/2013Uli HacksellCEOSell52,771$20.14$1,062,807.94View SEC Filing  
6/5/2013Felix BakerDirectorBuy2,340,314$14.34$33,560,102.76View SEC Filing  
5/15/2013Felix BakerDirectorBuy1,993,000$12.50$24,912,500.00View SEC Filing  
4/12/2013Glenn BaityVPSell60,000$12.42$745,200.00View SEC Filing  
4/11/2013Thomas H AasenCFOSell40,000$11.06$442,400.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

ACADIA Pharmaceuticals (NASDAQ ACAD) News Headlines

Source:
DateHeadline
ACADIA Pharmaceuticals (ACAD) Cut to "Hold" at Zacks Investment ResearchACADIA Pharmaceuticals (ACAD) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 15 at 4:28 PM
Interesting ACAD Put And Call Options For March 2nd - NasdaqInteresting ACAD Put And Call Options For March 2nd - Nasdaq
www.nasdaq.com - January 11 at 3:24 PM
3 Keys for Acadia Pharmaceuticals to Succeed in 2018 - Motley Fool3 Keys for Acadia Pharmaceuticals to Succeed in 2018 - Motley Fool
www.fool.com - January 11 at 7:46 AM
ACADIA Pharmaceuticals: Due For A Rebound - Seeking Alpha - Seeking AlphaACADIA Pharmaceuticals: Due For A Rebound - Seeking Alpha - Seeking Alpha
seekingalpha.com - January 9 at 8:43 AM
Today’s Research Reports on Stocks to Watch: ACADIA Pharmaceuticals Inc. and Exact Sciences CorporationToday’s Research Reports on Stocks to Watch: ACADIA Pharmaceuticals Inc. and Exact Sciences Corporation
finance.yahoo.com - January 9 at 8:43 AM
$45.04 Million in Sales Expected for ACADIA Pharmaceuticals Inc. (ACAD) This Quarter$45.04 Million in Sales Expected for ACADIA Pharmaceuticals Inc. (ACAD) This Quarter
www.americanbankingnews.com - January 7 at 9:10 AM
Traders Buy Large Volume of ACADIA Pharmaceuticals Put Options (ACAD)Traders Buy Large Volume of ACADIA Pharmaceuticals Put Options (ACAD)
www.americanbankingnews.com - January 7 at 3:40 AM
Acadia Remains Significantly Undervalued - Seeking AlphaAcadia Remains Significantly Undervalued - Seeking Alpha
seekingalpha.com - January 6 at 3:24 PM
Laura Brege Sells 25,000 Shares of ACADIA Pharmaceuticals Inc. (ACAD) StockLaura Brege Sells 25,000 Shares of ACADIA Pharmaceuticals Inc. (ACAD) Stock
www.americanbankingnews.com - January 4 at 9:30 PM
Insider Selling: ACADIA Pharmaceuticals Inc. (ACAD) EVP Sells 74,321 Shares of StockInsider Selling: ACADIA Pharmaceuticals Inc. (ACAD) EVP Sells 74,321 Shares of Stock
www.americanbankingnews.com - January 4 at 9:28 PM
Annual JP Morgan Healthcare Conference on January 9, 2018 - Business Wire (press release)Annual JP Morgan Healthcare Conference on January 9, 2018 - Business Wire (press release)
www.businesswire.com - January 4 at 8:02 AM
Is There An Opportunity With ACADIA Pharmaceuticals Inc’s (NASDAQ:ACAD) 40.91% Undervaluation?Is There An Opportunity With ACADIA Pharmaceuticals Inc’s (NASDAQ:ACAD) 40.91% Undervaluation?
finance.yahoo.com - January 4 at 8:02 AM
ACADIA Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference on January 9, 2018ACADIA Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference on January 9, 2018
finance.yahoo.com - January 2 at 3:29 PM
ACADIA Pharmaceuticals Inc. (ACAD) Receives Average Rating of "Buy" from BrokeragesACADIA Pharmaceuticals Inc. (ACAD) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - January 2 at 1:42 PM
ACADIA Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ACAD-US : January 1, 2018ACADIA Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ACAD-US : January 1, 2018
finance.yahoo.com - January 1 at 3:23 PM
ETFs with exposure to ACADIA Pharmaceuticals, Inc. : January 1, 2018ETFs with exposure to ACADIA Pharmaceuticals, Inc. : January 1, 2018
finance.yahoo.com - January 1 at 3:23 PM
BidaskClub Upgrades ACADIA Pharmaceuticals (ACAD) to HoldBidaskClub Upgrades ACADIA Pharmaceuticals (ACAD) to Hold
www.americanbankingnews.com - December 27 at 10:28 PM
ACADIA Pharmaceuticals, Inc. :ACAD-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017ACADIA Pharmaceuticals, Inc. :ACAD-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017
finance.yahoo.com - December 27 at 9:54 AM
Why the Earnings Streak Will Continue for ACADIA Pharmaceuticals (ACAD)Why the Earnings Streak Will Continue for ACADIA Pharmaceuticals (ACAD)
finance.yahoo.com - December 26 at 1:03 PM
ETFs with exposure to ACADIA Pharmaceuticals, Inc. : December 21, 2017ETFs with exposure to ACADIA Pharmaceuticals, Inc. : December 21, 2017
finance.yahoo.com - December 21 at 3:24 PM
First Week of ACAD February 2018 Options TradingFirst Week of ACAD February 2018 Options Trading
www.nasdaq.com - December 20 at 3:23 PM
Minerva Initiates Phase III Study on Schizophrenia CandidateMinerva Initiates Phase III Study on Schizophrenia Candidate
finance.yahoo.com - December 20 at 3:23 PM
ACADIA Pharmaceuticals Inc. (ACAD) Expected to Announce Earnings of -$0.58 Per ShareACADIA Pharmaceuticals Inc. (ACAD) Expected to Announce Earnings of -$0.58 Per Share
www.americanbankingnews.com - December 20 at 3:21 AM
With -14.1% Earnings Drop Lately, Did ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) Underperform Its Industry?With -14.1% Earnings Drop Lately, Did ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) Underperform Its Industry?
finance.yahoo.com - December 18 at 7:42 AM
Stock Review for Biotechs Investors -- Bioverativ, ACADIA Pharma, Inovio Pharma, and Biogen - PR Newswire (press release)Stock Review for Biotech's Investors -- Bioverativ, ACADIA Pharma, Inovio Pharma, and Biogen - PR Newswire (press release)
www.prnewswire.com - December 15 at 7:43 AM
Shires New Formulation of Oncaspar Gets Approval in EuropeShire's New Formulation of Oncaspar Gets Approval in Europe
www.msn.com - December 14 at 3:24 PM
Shire's New Formulation of Oncaspar Gets Approval in EuropeShire's New Formulation of Oncaspar Gets Approval in Europe
finance.yahoo.com - December 14 at 3:24 PM
ACADIA Pharmaceuticals Announces Appointment of Damien McDevitt, Ph.D., as Senior Vice President, Corporate ... - Business Wire (press release)ACADIA Pharmaceuticals Announces Appointment of Damien McDevitt, Ph.D., as Senior Vice President, Corporate ... - Business Wire (press release)
www.businesswire.com - December 14 at 7:49 AM
ACADIA Pharmaceuticals Announces Appointment of Damien McDevitt, Ph.D., as Senior Vice President, Corporate DevelopmentACADIA Pharmaceuticals Announces Appointment of Damien McDevitt, Ph.D., as Senior Vice President, Corporate Development
finance.yahoo.com - December 13 at 3:24 PM
Glaxo's Nucala Label Expansion Application Gets FDA ApprovalGlaxo's Nucala Label Expansion Application Gets FDA Approval
finance.yahoo.com - December 13 at 3:24 PM
Cramer Remix: Acadia is the most volatile stock I’ve ever covered — and it’s worth speculating onCramer Remix: Acadia is the most volatile stock I’ve ever covered — and it’s worth speculating on
finance.yahoo.com - December 12 at 3:23 PM
Albany Molecular Research (AMRI) vs. ACADIA Pharmaceuticals (ACAD) Head to Head ReviewAlbany Molecular Research (AMRI) vs. ACADIA Pharmaceuticals (ACAD) Head to Head Review
www.americanbankingnews.com - December 9 at 11:28 AM
Today’s Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Moleculin BiotechToday’s Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Moleculin Biotech
finance.yahoo.com - December 6 at 8:13 AM
Can Acadia Pharmaceuticals Be A Prudent Bet For Long-Term Investors? - Seeking AlphaCan Acadia Pharmaceuticals Be A Prudent Bet For Long-Term Investors? - Seeking Alpha
seekingalpha.com - December 5 at 7:49 AM
Heres How Acadia Pharmaceuticals Crushed It in 2017 - Motley FoolHere's How Acadia Pharmaceuticals Crushed It in 2017 - Motley Fool
www.fool.com - December 4 at 3:23 PM
ACADIA Pharmaceuticals Inc. (ACAD) Expected to Announce Quarterly Sales of $45.04 MillionACADIA Pharmaceuticals Inc. (ACAD) Expected to Announce Quarterly Sales of $45.04 Million
www.americanbankingnews.com - December 4 at 12:52 PM
Here's How Acadia Pharmaceuticals Crushed It in 2017Here's How Acadia Pharmaceuticals Crushed It in 2017
finance.yahoo.com - December 4 at 7:52 AM
 Brokerages Anticipate ACADIA Pharmaceuticals Inc. (ACAD) to Post -$0.59 EPS Brokerages Anticipate ACADIA Pharmaceuticals Inc. (ACAD) to Post -$0.59 EPS
www.americanbankingnews.com - December 2 at 7:24 AM
Commercialisation Of Biologics: Benchmarking Leading PlayersCommercialisation Of Biologics: Benchmarking Leading Players
www.bizjournals.com - November 29 at 3:22 PM
ACADIA Pharmaceuticals Inc. (ACAD) Short Interest UpdateACADIA Pharmaceuticals Inc. (ACAD) Short Interest Update
www.americanbankingnews.com - November 27 at 11:32 PM
Acadia Pharmaceuticals: The Harmony Trial And Buyout Potential ... - Seeking AlphaAcadia Pharmaceuticals: The Harmony Trial And Buyout Potential ... - Seeking Alpha
seekingalpha.com - November 27 at 3:18 PM
Spectrum Doubles in 3 Months: What's Driving the Rally?Spectrum Doubles in 3 Months: What's Driving the Rally?
finance.yahoo.com - November 27 at 3:18 PM
ACADIA Pharmaceuticals Inc. (ACAD) Rating Lowered to Sell at ValuEngineACADIA Pharmaceuticals Inc. (ACAD) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - November 26 at 2:16 PM
ACAD January 2018 Options Begin TradingACAD January 2018 Options Begin Trading
www.nasdaq.com - November 22 at 9:03 PM
ACADIA Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference on November 28, 2017ACADIA Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference on November 28, 2017
finance.yahoo.com - November 21 at 3:59 PM
Opus Point Partners Management, LLC Buys Bioverativ Inc, ACADIA Pharmaceuticals Inc, United ... - NasdaqOpus Point Partners Management, LLC Buys Bioverativ Inc, ACADIA Pharmaceuticals Inc, United ... - Nasdaq
www.nasdaq.com - November 18 at 8:23 AM
ACADIA Pharmaceuticals Sees Unusually Large Options Volume (ACAD)ACADIA Pharmaceuticals Sees Unusually Large Options Volume (ACAD)
www.americanbankingnews.com - November 17 at 1:26 AM
Billionaire Israel “Izzy” Englander Bets on Troubled Pharma Giants Teva and Valeant, Nixes AcadiaBillionaire Israel “Izzy” Englander Bets on Troubled Pharma Giants Teva and Valeant, Nixes Acadia
finance.yahoo.com - November 16 at 3:39 PM
ACADIA Pharmaceuticals Inc. (ACAD) Upgraded at Zacks Investment ResearchACADIA Pharmaceuticals Inc. (ACAD) Upgraded at Zacks Investment Research
www.americanbankingnews.com - November 15 at 9:00 PM
ACADIA Pharmaceuticals Has This Top Analyst Even More Positive on PDP Drug Nuplazid’s OpportunityACADIA Pharmaceuticals Has This Top Analyst Even More Positive on PDP Drug Nuplazid’s Opportunity
finance.yahoo.com - November 13 at 5:23 PM

SEC Filings

ACADIA Pharmaceuticals (NASDAQ:ACAD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

ACADIA Pharmaceuticals (NASDAQ:ACAD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

ACADIA Pharmaceuticals (NASDAQ ACAD) Stock Chart for Tuesday, January, 16, 2018

Loading chart…

This page was last updated on 1/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.